

REVION HEALTH CARE (UK) LIMITED

INTER OFFICE MEMORANDUM



TO : Mr. C. R. Bishop

DATE: 24th April, 1985

FROM : E. R. James

REF: ERJ/cds

SUBJECT : HEAT TREATED FACTORATE - NIBS & C CONCERN OVER USE OF NAMED PATIENT SUPPLY

COPIES TO :

P B Lloyd
J T A Moore
P B Christie
Luckhurst
L Field
N Randall
C G Blatchford
D Cockayne
C J Collins
G T S Barham
J D Michelmores
C J Swartz
File (3)

Dr. Trevor Barrowcliffe of NIBS & C has expressed concern over the use of Named Patient Supplies to provide our H. T. Factorate to the UK market as we now have Product Licence for the supply of heat-treated product. He has advised that NIBS & C are seeking, with the DHSS, ways of applying pressure upon supplying companies to have this product released by the procedure detailed on our licence.

It is, therefore, important that our May 2nd meeting agrees a date when we will revert to normal release procedures for new production from Kankakee and this this is then advised to NIBS & C; I understand from Mrs Field, that this should be possible by Mid-May if Kankakee fulfil our current orders.

It must also be borne in mind that release by the named patient 'route' while ensuring faster turn-round does create a significant additional workload throughout PIC Dept., Q.C. Division, M & T Division and Warehouse.

Because Armour Pharma GmbH are not registered on our licence for the supply of Factorate, all the returns from UK Haemophilia Centre being heat-treated at Eschwege will continue to be supplied on a named patient basis.

GRO-C

E. R. JAMES